191 related articles for article (PubMed ID: 33050433)
1. Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms.
Ezzeldin E; Abo-Talib NF; Tammam MH; Asiri YA; Amr AEE; Almehizia AA
Molecules; 2020 Oct; 25(20):. PubMed ID: 33050433
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies.
Baker MM; Hammad SF; Belal TS
Drug Dev Ind Pharm; 2019 Jul; 45(7):1111-1119. PubMed ID: 30929537
[TBL] [Abstract][Full Text] [Related]
3. Chemometrically Assisted Development of Ultra-High-Performance Liquid Chromatography Method for the Simultaneous Quantification of Sofosbuvir, Daclatasvir and Ledipasvir in Pharmaceutical Dosage Forms.
Labidi A; El Atrache LL
J Chromatogr Sci; 2020 Jan; 57(10):910-919. PubMed ID: 31644804
[TBL] [Abstract][Full Text] [Related]
4. Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs.
Rageh AH; Abdel-Aal FAM; Pyell U
J Chromatogr A; 2020 Apr; 1616():460795. PubMed ID: 31918849
[TBL] [Abstract][Full Text] [Related]
5. Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
Ibrahim AE; Hashem H; Elhenawee M; Saleh H
J Sep Sci; 2018 Apr; 41(8):1734-1742. PubMed ID: 29297968
[TBL] [Abstract][Full Text] [Related]
6. Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir.
Baker MM; El-Kafrawy DS; Mahrous MS; Belal TS
Ann Pharm Fr; 2018 Jan; 76(1):16-31. PubMed ID: 28842163
[TBL] [Abstract][Full Text] [Related]
7. Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum.
Majnooni MB; Miraghaee SS; Keshavarzi S; Mohammadi B; Sajadimajd S; Hatami R; Bahrami G
J Pharm Biomed Anal; 2021 Feb; 195():113860. PubMed ID: 33387837
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in fixed dose combination tablets and plasma.
Mehmood Y; Khan IU; Shahzad Y; Khalid SH; Irfan M; Asghar S; Yousaf AM; Hussain T; Khalid I
Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1835-1842. PubMed ID: 31680080
[TBL] [Abstract][Full Text] [Related]
9. Development of a highly sensitive high-performance thin-layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations.
Saraya RE; Elhenawee M; Saleh H
J Sep Sci; 2018 Sep; 41(18):3553-3560. PubMed ID: 30048040
[TBL] [Abstract][Full Text] [Related]
10. Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.
Zidan DW; Hassan WS; Elmasry MS; Shalaby AA
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():73-81. PubMed ID: 29660665
[TBL] [Abstract][Full Text] [Related]
11. Development a validated highly sensitive LC-MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study.
Abdallah OM; Abdel-Megied AM; Gouda AS
J Pharm Biomed Anal; 2017 Sep; 143():305-310. PubMed ID: 28645021
[TBL] [Abstract][Full Text] [Related]
12. Spectroflurimetric estimation of the new antiviral agent ledipasvir in presence of sofosbuvir.
Salama FM; Attia KA; Abouserie AA; El-Olemy A; Abolmagd E
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Feb; 190():513-517. PubMed ID: 28968574
[TBL] [Abstract][Full Text] [Related]
13. Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS.
van Seyen M; de Graaff Teulen MJA; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Mar; 1110-1111():15-24. PubMed ID: 30776611
[TBL] [Abstract][Full Text] [Related]
14. A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma.
Elkady EF; Aboelwafa AA
J AOAC Int; 2016 Sep; 99(5):1252-9. PubMed ID: 27480956
[TBL] [Abstract][Full Text] [Related]
15. Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma.
Mohammed BS; Derayea SM; Hamad AE
J Chromatogr Sci; 2021 May; 59(6):576-583. PubMed ID: 33822903
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of the brand new two-drug combination for the treatment of hepatitis C: Sofosbuvir/ledipasvir using smart spectrophotometric methods manipulating ratio spectra.
Eissa MS
Spectrochim Acta A Mol Biomol Spectrosc; 2017 Aug; 183():362-370. PubMed ID: 28460317
[TBL] [Abstract][Full Text] [Related]
17. RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form.
Hussain Shah SS; Nasiri MI; Sarwar H; Ali A; S Naqvi SB; Anwer S; Kashif M
Pak J Pharm Sci; 2021 May; 34(3):951-956. PubMed ID: 34602418
[TBL] [Abstract][Full Text] [Related]
18. Stability Indicating RP-HPLC Method for Estimation of Potential Impurities in Ledipasvir and Characterization of a New Degradation Impurity.
Siva Kumar R; Sravan Kumar KV; Kondareddy L; Yogeshwara KR; Manish G; Jeenet J; Nitesh K
J Chromatogr Sci; 2018 May; 56(5):383-395. PubMed ID: 29474520
[TBL] [Abstract][Full Text] [Related]
19. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Youssef AA; Magdy N; Hussein LA; El-Kosasy AM
J Chromatogr Sci; 2019 Aug; 57(7):636-643. PubMed ID: 31063182
[TBL] [Abstract][Full Text] [Related]
20. A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma.
Ariaudo A; Favata F; De Nicolò A; Simiele M; Paglietti L; Boglione L; Cardellino CS; Carcieri C; Di Perri G; D'Avolio A
J Pharm Biomed Anal; 2016 Jun; 125():369-75. PubMed ID: 27131146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
